Skip to Main Content

For patients 6 years and older with ADHD

DYANAVEL XR (amphetamine) tablet is proven to be bioequivalent to DYANAVEL XR oral suspension.1 Learn more about Dyanavel XR Tablet

DYANAVEL XR Oral Suspension Starts Fast and Lasts2

Statistically Significant Improvement in Attention and Behavior With DYANAVEL XR vs Placebo2

Graph: Statistically Significant Improvement In Attention and Behavior With DYANAVEL XR Oral Suspension vs Placebo

A lower SKAMP* score indicates an improvement in attention and behavior2

The primary endpoint—change from predose in SKAMP-Combined score at 4 hours postdose—was significantly improved in the DYANAVEL XR group compared with that in the placebo group2

LS mean: DYANAVEL XR oral suspension, -8.8; placebo, 6.0

LS mean difference: -14.8 (95% CI: -17.9, -11.6; P<0.0001)

PERMP Scores Were Significantly Better With DYANAVEL XR for up to 13 Hours Postdose vs Placebo2

Graph: PERMP Scores Were Better With DYANAVEL XR Oral Suspension For Up To 13 Hours Postdose vs. Placebo
  • One of the secondary endpoints was change from predose PERMP scores at 1, 2, 4, 6, 8, 10, 12, and 13 hours postdose2
  • PERMP is a 10-minute written test with the number of problems attempted and the number of problems answered correctly used as measures of a patient’s performance2
  • PERMP scores (problems attempted and problems answered correctly) were significantly improved with DYANAVEL XR (amphetamine) at all postdose time points compared with placebo (P<0.0001 for both)2

PERMP Test Examples

The PERMP is a validated, time-sensitive, skill-adjusted test consisting of math problems to be completed at multiple time points (administration of serial PERMPs). It is a robust, objective measure of the ability to initiate a task, self-monitor/stay on task, and complete written seatwork. The PERMP does not test for mathematical ability or the ability to learn math because the difficulty of problems is adjusted to the existing math skill level of each participant.3

Shown below are examples of PERMP test results from an actual patient in the clinical study.

Open-Label Period

Practice Laboratory School Day (Vist 7)

DYANAVEL XR at 1 hour

Dyanavel XR Double-Blind Period Practice Laboratory School Day DYANAVEL XR Oral Suspension at 1 Hour

Double-Blind Period

Complete Laboratory School Day (Vist 8)

Placebo at 1 hour

Dyanavel XR Double-Blind Period Practice Laboratory School Day Placebo at 1 Hour

Study Design: One-week, randomized, double-blind, placebo-controlled laboratory classroom assessment of attention and behavior, scored by teachers and raters using the SKAMP rating scale in children aged 6 to 12 years (N=108) who met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria for ADHD. Classroom assessment followed a 5-week, open-label, dose-optimization period, where subjects initially received 2.5 mg or 5 mg DYANAVEL XR once daily in the morning. The dose was titrated by 2.5 mg to 10 mg every 4 to 7 days until an optimal dose or the maximum dose of 20 mg/day was reached. The primary endpoint was change from predose in SKAMP-Combined score at 4 hours postdose. Key secondary endpoints were onset and duration of clinical effect. The change in scores from predose SKAMP-Combined scores at postdose time points (1, 2, 4, 6, 8, 10, 12, and 13 hours) was used to evaluate key secondary efficacy parameters.2

Safety data for
DYANAVEL XR oral suspension caret

*

The SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) rating scale, often used in clinical trials, is a validated rating instrument, used by trained raters to specifically measure the observed classroom manifestations of ADHD. The items of the SKAMP are specific for place (the classroom) and time (a typical class period). The scale’s items describe typical behaviors in a classroom setting, and additional items that describe behaviors associated with ADHD in the classroom. The SKAMP method of assessment has been demonstrated to be a sensitive measure of attention and behavior within a lab classroom setting.4

 

ADHD, Attention Deficit Hyperactivity Disorder; CI, confidence interval; LS, least squares; PERMP, Permanent Product Measure of Performance.

 

References: 1. Pardo A, Kando JC, King TR, Rafla E, Herman BK. CNS Spectr. 2020;25(6):774-781. 2. Childress AC, Wigal SB, Brams MN, et al. J Child Adolesc Psychopharmacol. 2018;28(5):306-313. 3. Data on file. Tris Pharma, Inc. 4. Wigal SB, Gupta S, Guinta D, Swanson JM. Psychopharmacol Bull. 1998;34(1):47-53.

IMPORTANT SAFETY INFORMATION

isi open close button

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Dyanavel XR, Quillivant XR, QuilliChew ER, and other amphetamine-containing or methylphenidate-containing products, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Dyanavel XR, Quillivant XR, QuilliChew ER, and other amphetamine-containing or methylphenidate-containing products, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

  • Dyanavel XR (amphetamine), Quillivant XR (methylphenidate HCl), and QuilliChew ER (methylphenidate HCl) are contraindicated:
    • in patients known to be hypersensitive to amphetamine, methylphenidate, or other components of Dyanavel XR, Quillivant XR, and QuilliChew ER. Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been reported.
    • in patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs, because of risk of hypertensive crisis.
  • Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, and other serious cardiac problems. Sudden death, stroke, and myocardial infarction have been reported in adults treated with CNS stimulants at recommended doses. Sudden death has been reported in pediatric patients with structural cardiac abnormalities and other serious cardiac problems when taking CNS stimulants at recommended doses for ADHD. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during treatment with Dyanavel XR, Quillivant XR, and QuilliChew ER.
  • CNS stimulants cause increase in blood pressure (mean increase approximately 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Monitor all patients for tachycardia and hypertension.
  • CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder. They may induce a mixed/manic episode in patients with bipolar disorder. Assess for presence of bipolar disorder prior to initiating treatment. At recommended doses, stimulants may cause psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania, in patients without prior history of psychotic illness or mania. If such symptoms occur, consider discontinuing Dyanavel XR, Quillivant XR, or QuilliChew ER.
  • CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients with ADHD; monitor weight and height during treatment with Dyanavel XR, Quillivant XR, and QuilliChew ER. Treatment may need to be interrupted in children not growing or gaining weight as expected.
  • CNS stimulants are associated with peripheral vasculopathy, including Raynaud's phenomenon. Signs and symptoms are usually intermittent and mild; very rare sequelae include digital ulceration and/or soft tissue breakdown. Careful observation for digital changes is necessary during treatment with ADHD stimulants.
  • Cases of painful and prolonged penile erections and priapism have been reported with methylphenidate products. Immediate medical attention should be sought if signs or symptoms of prolonged penile erections or priapism are observed.
  • Serotonin syndrome risk is increased when Dyanavel XR is co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), MAOIs, and during overdosage situations. If it occurs, discontinue Dyanavel XR and any concomitant serotonergic agents immediately, and initiate supportive treatment.
  • QuilliChew ER contains phenylalanine, a component of aspartame, and can be harmful to patients with phenylketonuria (PKU).
  • Most common adverse reactions observed with amphetamine products: dry mouth, anorexia, weight loss, abdominal pain, nausea, insomnia, restlessness, emotional lability, dizziness, and tachycardia.
  • Based on limited experience with Dyanavel XR in controlled trials, the adverse reaction profile of Dyanavel XR appears similar to other amphetamine extended-release products. The most common (≥2% in the Dyanavel XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 108 patients with ADHD (aged 6 to 12 years) were: epistaxis (Dyanavel XR 4%, placebo 0%), allergic rhinitis (4%, 0%) and upper abdominal pain (4%, 2%).
  • Based on accumulated data from other methylphenidate products, the most common (≥5% and twice the rate of placebo) adverse reactions are: appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, blood pressure increased.
  • There is limited experience with Quillivant XR and QuilliChew ER in controlled trials.
    • Quillivant XR: The most common (≥2% in the Quillivant XR group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 45 ADHD patients (ages 6 to 12 years) in Quillivant XR compared to placebo were affect lability (9% Quillivant XR, 2% placebo), excoriation (4%, 0%), initial insomnia (2%, 0%), tic (2%, 0%), decreased appetite (2%, 0%), vomiting (2%, 0%), motion sickness (2%, 0%), eye pain (2%, 0%), and rash (2%, 0%).
    • QuilliChew ER: The most common (≥2% in the QuilliChew ER group and greater than placebo) adverse reactions reported in the Phase 3 controlled study conducted in 90 pediatric subjects (ages 6 to 12 years) in QuilliChew ER compared to placebo were decreased appetite (2.4% QuilliChew ER, 0% placebo), aggression (2.4%, 0%), emotional poverty (2.4%, 0%), nausea (2.4%, 0%), headache (2.4%, 0%), and weight decreased (2.4%, 0%).
  • Dyanavel XR, Quillivant XR, and QuilliChew ER use during pregnancy may cause fetal harm.
  • Breastfeeding is not recommended during treatment with Dyanavel XR, Quillivant XR, or QuilliChew ER.

INDICATION

Dyanavel XR, Quillivant XR, and QuilliChew ER are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

See Full Prescribing Information for Dyanavel XR, Quillivant XR, and QuilliChew ER, including Boxed Warning regarding Abuse and Dependence.

This site is intended for healthcare professionals in the United States, its territories, and Puerto Rico.